http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113788822-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bbd1b2ec9da9bfeadfe8092cc7d23ea6 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 |
| filingDate | 2021-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a834c5f509c6194f556b2ae24a9c6d9e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1498023dbd518d812febde3e7add5bb1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_764737aac222788258dc516eeb1aa7b6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4e015256fcbf4c55b5055fd9a3c1b47c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_782ddf25e475456805d71c661b083208 |
| publicationDate | 2021-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113788822-A |
| titleOfInvention | A novel naringenin pyrimidine hydrazone derivative and its preparation method and application |
| abstract | The invention discloses a novel naringenin pyrimidine hydrazone derivative, a preparation method and application thereof, and the molecular formula is C 19 H 16 N 4 O 4 . The present invention adopts the MTT method to study the antitumor activity of naringenin-4-pyrimidine hydrazone derivatives, and the results show that the naringenin-4-pyrimidine hydrazone prepared by the present invention has an antitumor effect on human gastric cancer cells BGC-823 and human lung cancer cells A549. All have inhibitory effect on proliferation, and the inhibitory activity is 2-5 times higher than that of the raw material drug naringenin itself, and the inhibitory effect is greatly enhanced. The IC50 of the ‑823 is only 8.59 μM. The results show that the naringenin-4-pyrimidine hydrazone of the present invention has a good inhibitory effect on the proliferation of the two types of tumor cells in the experiment, and the inhibitory activity on the human gastric cancer cell BGC-823 is more significant, which is obviously stronger than that of the crude drug naringenin. And the control example naringenin-4-pyridine hydrazone, is an anti-tumor compound with important application prospects. |
| priorityDate | 2021-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 39.